STSA
$3.83
Satsuma Pharmaceuticals
($.11)
(2.79%)
STSA
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.67)
Revenue:  $0.00 Mil
Tuesday
Nov 10
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when STSA reports earnings?
Beat
Meet
Miss

Where is STSA's stock price going from here?
Up
Flat
Down
Stock chart of STSA
Analysts
Summary of analysts' recommendations for STSA
Score
Grade
Pivots
Resistance
$4.16
$4.08
$3.95

$3.87

Support
$3.74
$3.66
$3.53
Tweet
Growth
Description
Satsuma Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company's product consists of STS101, which are in clinical stage. Satsuma Pharmaceuticals Inc. is based in San Francisco, United States.